Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Nuvation Bio Inc. (NYSE:NUVB) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.6250.

A number of equities analysts recently commented on NUVB shares. Royal Bank Of Canada raised their target price on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. HC Wainwright cut their price target on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Truist Financial set a $13.00 price objective on Nuvation Bio in a research note on Tuesday, January 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a research report on Tuesday, February 10th.

Nuvation Bio Stock Up 1.5%

Shares of NUVB stock opened at $4.44 on Friday. The company has a current ratio of 6.95, a quick ratio of 6.81 and a debt-to-equity ratio of 0.15. Nuvation Bio has a 12 month low of $1.54 and a 12 month high of $9.75. The stock has a market cap of $1.52 billion, a P/E ratio of -7.39 and a beta of 1.50. The company has a 50 day simple moving average of $5.82 and a two-hundred day simple moving average of $5.60.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The business had revenue of $41.87 million for the quarter, compared to analysts’ expectations of $36.82 million. On average, research analysts expect that Nuvation Bio will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Nuvation Bio

Several large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Nuvation Bio in the second quarter worth $207,000. Tema Etfs LLC purchased a new position in shares of Nuvation Bio during the 2nd quarter valued at $272,000. Aisling Capital Management LP lifted its stake in shares of Nuvation Bio by 16.5% during the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock valued at $10,954,000 after buying an additional 419,650 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Nuvation Bio by 16.8% in the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock worth $11,691,000 after buying an additional 864,194 shares during the period. Finally, CWM LLC boosted its holdings in Nuvation Bio by 169.5% in the 3rd quarter. CWM LLC now owns 102,328 shares of the company’s stock worth $379,000 after buying an additional 64,365 shares during the period. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.